Association of social and cognitive impairment and biomarkers in autism spectrum disorders

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Alabdali, Altaf ^a   Al Ayadhi, Laila ^a   El Ansary, Afaf ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Autism spectrum disorders; Childhood autism rating scale; Interferon induced protein 16; Neuroinflammation; Neurotransmitters; Oxytocin; Social responsiveness scale

Indexed keywords

4 AMINOBUTYRIC ACID; BIOLOGICAL MARKER; CYTOKINE; DOPAMINE; OXYTOCIN; PROTEIN IFI16; SEROTONIN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTISOCIAL PERSONALITY DISORDER; ARTICLE; AUTISM; CHILD; CHILDHOOD AUTISM RATING SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; PROTEIN BLOOD LEVEL; RATING SCALE; SAUDI ARABIA; SEX DIFFERENCE; SOCIAL ADAPTATION; THROMBOCYTE FREE PLASMA;

AREA UNDER CURVE; BIOLOGICAL MARKERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MITOCHONDRIAL PROTEINS; NEUROTRANSMITTER AGENTS; OXYTOCIN; STATISTICS AS TOPIC;

EID: 84892165503     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-4     Document Type: Article

References (73)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 2000, Washington, DC: American Psychiatric Association, 4, American Psychiatric Association.
2. Esposito G, Venuti P. Analysis of toddlers' gait after six months of independent walking to identify autism: a preliminary study. Percept Mot Skills 2008, 106(1):259-269. 10.2466/pms.106.1.259-269, 18459375.
3. Lord C, Rutter M, le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994, 24(5):659-685. 10.1007/BF02172145, 7814313.
4. Baranek G. Sensory and motor features in autism: assessment and intervention. Handbook of Autism and Pervasive Developmental Disorders 2005, 831-857. Hoboken NJ: John Wiley & Sons Inc, Volkmar FR, Paul R, Klin A, Cohen D, 3.
5. Ozonoff S, Young GS, Goldring S, Greiss-Hess L, Herrera AM, Steele J, Macari S, Hepburn S, Rogers SJ. Gross motor development, movement abnormalities, and early identification of autism. J Autism Dev Disord 2008, 38(4):644-656. 10.1007/s10803-007-0430-0, 17805956.
6. Esposito G, Venuti P, Maestro S, Muratori F. An exploration of symmetry in early autism spectrum disorders: analysis of lying. Brain Dev 2009, 31(2):131-138. 10.1016/j.braindev.2008.04.005, 18534798.
7. Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011, Article ID:297153.
8. Rogers SJ, Vismara LA. Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol 2008, 37:8-38. 10.1080/15374410701817808, 2943764, 18444052.
9. Kałuzna-Czaplińska J, Socha E, Rynkowski J. Determination of homovanillic acid and vanillylmandelic acid in urine of autistic children by gas chromatography/mass spectrometry. Med Sci Monit 2010, 16(9):445-450.
10. Hammock E, Veenstra-VanderWeele J, Yan Z, Kerr TM, Morris M, Anderson GM, Carter CS, Cook EH, Jacob S. Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems. J Am Acad Child Adolesc Psychiatry 2012, 51(7):712-721. 10.1016/j.jaac.2012.04.010, 3672055, 22721594.
11. Anderson GM, Hertzig ME, McBride PA. Platelet-poor plasma serotonin in autism. J Autism Dev Disord 2012, 42(7):1510-1514. 10.1007/s10803-011-1371-1, 21979109.
12. El-Ansary AK, Bacha AB, Ayahdi LY. Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia. Clin Biochem 2011, 44:1116-1120. 10.1016/j.clinbiochem.2011.06.982, 21763301.
13. Fatemi SH, Folsom TD, Reutiman TJ, Thuras PD. Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum 2009, 8(1):64-69. 10.1007/s12311-008-0075-3, 2732344, 19002745.
14. Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat Rec (Hoboken) 2011, 294(10):1646-1652. 10.1002/ar.21252, 3190183, 21901839.
15. Kubas B, Kułak W, Sobaniec W, Tarasow E, Lebkowska U, Walecki J. Metabolite alterations in autistic children: a 1H MR spectroscopy study. Adv Med Sci 2012, 57(1):152-156.
16. Al-Ayadhi LY. Altered oxytocin and vasopressin levels in autistic children in Central Saudi Arabia. Neurosciences (Riyadh) 2005, 10(1):47-50.
17. Ragini M, Banji O, Banji D, Pratusha G, Kumar K, Ananthula MR. Biomarkers in Autism. Int J Pharm Tech Res 2011, 3:1281-1289.
18. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162. 10.1038/npp.2011.205, 3238082, 21918508.
19. Leonard BE. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014, 48:261-267.
20. Laurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum 2005, 4:206-210. 10.1080/14734220500208846, 16147953.
21. Fatemi SH, Folsom TD, Reutiman TJ, Lee S. Expression of astrocytic markers aquaporin 4 and connexin 43 is altered in brains of subjects with autism. Synapse 2008, 62:501-507. 10.1002/syn.20519, 2697054, 18435417.
22. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007, 12:988-1000. 10.1038/sj.mp.4002006, 17457312.
23. Pacheco R, Gallart T, Lluis C, Franco R. Role of glutamate on T-cell mediated immunity. J Neuroimmunol 2007, 185:9-19. 10.1016/j.jneuroim.2007.01.003, 17303252.
24. Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ. GABA system dysfunction in autism and related disorders: From synapse to symptoms. Neurosci Biobehav Rev 2012, 36:2044-2055. 10.1016/j.neubiorev.2012.07.005, 22841562.
25. Hussman JP. Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. J Autism Dev Disord 2001, 31(2):247-248. 10.1023/A:1010715619091, 11450824.
26. Fatemi SH, Folsom TD, Kneeland RE, Liesch SB. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken) 2011, 294(10):1635-1645. 10.1002/ar.21299, 3177171, 21901840.
27. Singh VK. Plasma increase of interleukin-12 and interferon-gamma: pathological significance in autism. J Neuroimmunol 1996, 66:143-145. 10.1016/0165-5728(96)00014-8, 8964908.
28. El-Ansary A, Ben Bacha AG, Al-Ayadhi LY. Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia. J Neuroinflammation 2011, 8:142. 10.1186/1742-2094-8-142, 3213048, 21999440.
29. Wei H, Alberts I, Li X. Brain IL-6 and autism. Neuroscience 2013, 252(12 N):320-325.
30. El-Ansary A, Al-Ayadhi LY. Neuroinflammation in autism spectrum disorders. J Neuroinflammation 2012, 9:265. 10.1186/1742-2094-9-265, 3549857, 23231720.
31. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795. 10.1146/annurev.immunol.15.1.749, 9143706.
32. Mick KA. Diagnosing Autism: Comparison of the Childhood Autism Rating Scale (CARS) and the Autism Diagnostic Observation Schedule (ADOS).PhD Dissertation 2005, Kansas: Wichita State University.
33. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 2003, 33:427-433. 10.1023/A:1025014929212, 12959421.
34. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050. 10.1093/brain/awl279, 17071923.
35. Enticott PG, Kennedy HA, Rinehart NJ, Tonge BJ, Bradshaw JL, Fitzgerald PB. GABAergic activity in autism spectrum disorders: an investigation of cortical inhibition via transcranial magnetic stimulation. Neuropharmacology 2013, 68:202-209.
36. Blatt GJ. The neuropathology of autism. Scientifica (Cairo) 2012, 2012:703675. 3820437, 24278731.
37. Mendez MA, Horder J, Myers J, Coghlan S, Stokes P, Erritzoe D, Howes O, Lingford-Hughes A, Murphy D, Nutt D. The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology 2013, 68:195-201.
38. DeLorey TM, Handforth A, Anagnostaras SG, Homanics GE, Minassian BA, Asatourian A, Fanselow MS, Delgado-Escueta A, Ellison GD, Olsen RW. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci 1998, 18(20):8505-8514.
39. Colas D, Chuluun B, Warrier D, Blank M, Wetmore DZ, Buckmaster P, Garner CC, Heller HC. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. Br J Pharmacol 2013, 169(5):963-973. 10.1111/bph.12169, 23489250.
40. Meneses A. 5-HT systems: emergent targets for memory formation and memory alterations. Rev Neurosci 2013, 24(6):629-664.
41. Spivak B, Golubchik P, Mozes T, Vered Y, Nechmad A, Weizman A, Strous RD. Low platelet-poor plasma levels of serotonin in adult autistic patients. Neuropsychobiology 2004, 50(2):157-160. 10.1159/000079108, 15292671.
42. Mostafa GA, Al-Ayadhi LY. A lack of association between hyperserotonemia and the increased frequency of serum anti-myelin basic protein auto-antibodies in autistic children. J Neuroinflammation 2011, 22(8):71.
43. Connors SL. Prenatal β2-adrenergic receptor signaling and autism: dysmaturation and retained fetal function. Autism Current Theories and Evidence 2008, 147-182. Totowa: Humana Press, Zimmerman AW.
44. Marazziti D, Dell'Osso B, Baroni S, Vivarelli L, Masala F, Mungai F, Muratori F. The serotonin transporter is increased in platelets of autistic children. Trends in Autism Research 2004, 187-195. New York: Nova Science, Ryaskin OT.
45. Gorton GE, Swirsky-Sacchetti T, Sobel R, Samuel S, Gordon A. Neuropsychology of childhood mental disorders: interaction of phenomenological, neurobiological, and neuropsychological findings. Assessment of Neuropsychological Functions in Psychiatric Disorders 1999, 135-233. Washington DC: American Psychiatric Press, Avraham C.
46. Kuperman S, Beeghly JH, Burns TL, Tsai LY. Association of serotonin concentration to behavior and IQ in autistic children. J Autism Dev Disord 1987, 17(1):133-140. 10.1007/BF01487265, 3571137.
47. Gillberg C, Svennerholm L. CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 1987, 151:89-94. 10.1192/bjp.151.1.89, 2445409.
48. Toda Y, Mori K, Hashimoto T, Miyazaki M, Nozaki S, Watanabe Y, Kuroda Y, Kagami S. Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev 2006, 28:99-103. 10.1016/j.braindev.2005.05.005, 16168596.
49. Previc FH. Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Medical Hypotheses 2007, 68:46-60. 10.1016/j.mehy.2006.06.041, 16959433.
50. Narayan M, Srinath S, Anderson GM, Meundi DB. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry 1993, 33(8-9):630-635.
51. Field T, Diego M, Hernandez-Reif M, Figueiredo B, Deeds O, Ascencio A, Schanberg S. Cynthia Kuhn Prenatal dopamine and neonatal behavior and biochemistry. Infant Behav Dev 2008, 31:590-593. 10.1016/j.infbeh.2008.07.007, 2610266, 18774177.
52. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003, 23(6):2008-2013.
53. Schouwenburg MV, Aarts E, Cools R. Dopaminergic modulation of cognitive control: distinct roles for the prefrontal cortex and the basal ganglia. Curr Pharm Des 2010, 16:2026-2032. 10.2174/138161210791293097, 20370667.
54. Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, Belovich AN, Sahai MA, Cook EH, Gether U, McHaourab HS, Matthies HJ, Sutcliffe JS, Galli A. NIH ARRA Autism Sequencing Consortium De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry 2013, 18:1315-1323. 10.1038/mp.2013.102, 23979605, NIH ARRA Autism Sequencing Consortium.
55. Kaufman S, Friedman S. Dopamine β-hydroxylase. Pharmacol Rev 1965, 17:71-100.
56. Elston RC, Namboodiri KK, Hames CG. Segregation and linkage analyses of dopamine-β-hydroxylase activity. Hum Hered 1979, 29:284-292. 10.1159/000153059, 489028.
57. Robinson PD, Schutz CK, Macciardi F, White BN, Holden JJA. Genetically determined low maternal serum dopamine β-hydroxylase levels and the etiology of autism spectrum disorders. Am J Med Genet 2001, 100:30-36. 10.1002/ajmg.1187, 11337745.
58. Young LJ, Lim MM, Gingrich B, Insel TR. Cellular mechanisms of social attachment. Horm Behav 2001, 40(2):133-138. 10.1006/hbeh.2001.1691, 11534973.
59. Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001, 50(8):609-613. 10.1016/S0006-3223(01)01139-8, 11690596.
60. Lee HJ, Caldwell HK, Macbeth AH, Tolu SG, Young WS. A conditional knockout mouse line of the oxytocin receptor. Endocrinology 2008, 149(7):3256-3263. 10.1210/en.2007-1710, 2453083, 18356275.
61. Cao Y, Wu R, Tai F, Zhang X, Yu P, An X, Qiao X, Hao P. Neonatal paternal deprivation impairs social recognition and alters levels of oxytocin and estrogen receptor α mRNA expression in the MeA and NAcc, and serum oxytocin in mandarin voles. Horm Behav 2014, 6:57-65.
62. Lukas M, Neumann ID. Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav Brain Res 2013, 251:85-94.
63. Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM. Oxytocin levels in social anxiety disorder. CNS Neurosci Ther 2008, 14(3):165-170. 10.1111/j.1755-5949.2008.00051.x, 18801109.
64. El-Masry N, Soliman A, Abdel Moety H. Alterations of prolyl endopeptidase, oxytocin and vasopressin activity in the plasma of autistic children. Current Psychiatry 2010, 17(1):31-37.
65. Yrigollen CM, Han SS, Kochetkova A, Babitz T, Chang JT, Volkmar FR, Leckman JF, Grigorenko EL. Genes controlling affiliative behavior as candidate genes for autism. Biol Psychiatry 2008, 63:911-916. 10.1016/j.biopsych.2007.11.015, 2386897, 18207134.
66. Borden EC. Gene regulation and clinical roles for interferons in neoplastic diseases. Oncologist 1998, 3:198-203.
67. Garcia-Sastre A, Biron CA. Type I interferons and the virus-host relationship: a lesson in détente. Science 2006, 312:879-882. 10.1126/science.1125676, 16690858.
68. Conrady CD, Zheng M, Mandal NA, van Rooijen N, Carr DJ. IFN-α-driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal Immunol 2013, 6(1):45-55. 10.1038/mi.2012.46, 3449026, 22692455.
69. Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K, Persico AM. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008, 30(3):303-311. 10.1016/j.nbd.2008.01.012, 2693090, 18378158.
70. Santana-de Anda K, Gómez-Martín D, Soto-Solís R, Alcocer-Varela J. Plasmacytoid dendritic cells: key players in viral infections and autoimmune diseases. Semin Arthritis Rheum 2013, 43(1):131-136. 10.1016/j.semarthrit.2012.12.026, 23462050.
71. Gugliesi F, Mondini M, Ravera R, Robotti A, de Andrea M, Gribaudo G, Gariglio M, Landolfo S. Up-regulation of the interferon-inducible IFI16 gene by oxidative stress triggers p53 transcriptional activity in endothelial cells. J LeukocBiol 2005, 77(5):820-829.
72. Lam S, Li Q, Wei R, Zhang X, Chua S, McAlonan GM. Oxygen restriction of neonate rats elevates HIF-1a, IL-6, NF-kB and caspases-3 protein levels: possible relationship to neurodevelopmental disorders. Abstracts of the 3rd Biennial Schizophrenia Int Res Conf/Schizophr Res 2012, 136(Supplement 1):S1-S375.
73. Malik M, Tauqeer Z, Sheikh AM, Wen G, Nagori A, Yang K, Brown WT, Li X. NF-κB signaling in the brain of autistic subjects. Mediators Inflamm 2011, Article ID:785265.